

Interlaboratory Evaluations of a Standardized Quantitative Test Method for Determining the Bactericidal and Tuberculocidal Efficacy of Antimicrobial Substances on Hard Non-Porous Surfaces

Stephen F. Tomasino, Rebecca M. Pines, Darla M. Goeres, Albert E. Parker

© This manuscript version is made available under the CC-BY-NC-ND 4.0 license <https://creativecommons.org/licenses/by-nc-nd/4.0/>

1 **Interlaboratory Evaluations of a Standardized Quantitative Test Method for**
2 **Determining the Bactericidal and Tuberculocidal Efficacy of Antimicrobial**
3 **Substances on Hard Non-Porous Surfaces**

4 Tomasino, S., Pines, R., Goeres, D. and Parker, A.

5 **Abstract**

6 The development, validation, and use of new quantitative methodologies for testing the
7 effectiveness of antimicrobial products are necessary to meet the regulatory challenges
8 associated with an ever-changing marketplace, novel product claims, new infection control
9 practices, and the emergence of new clinical pathogens. A series of four interlaboratory studies
10 were conducted in a standardized manner on an interim quantitative method for testing liquid
11 treatments against bacteria to assess its statistical performance. The Quantitative Method, a
12 derivative of ASTM E2197, is designed to enumerate the number of viable microbes remaining
13 on a test carrier following exposure to a liquid antimicrobial treatment; a log₁₀ reduction (LR) in
14 viable bacteria is calculated based on the difference between the mean log₁₀ density values of the
15 untreated control and treated carriers. The Quantitative Method uses 1 cm diameter disks
16 (carriers) of brushed stainless steel as the material to represent a hard, non-porous surface. The
17 LR value is used as the measure of product effectiveness, where higher LR values are indicative
18 of greater microbial kill. The test microbes were *Staphylococcus aureus*, *Pseudomonas*
19 *aeruginosa*, and *Mycobacterium terrae*. The liquid antimicrobial treatments used in these studies
20 were highly relevant to those in the marketplace and provided a wide range of mean LR
21 outcomes. The focus of the statistical assessment was on the repeatability of the LRs across
22 experiments within a lab (S_r) and the reproducibility of the LRs across labs (S_R). Due to the

23 additional sources of variability, the S_R is expected to be higher than the variability within a
24 laboratory (S_r); this was observed in the studies reported here. Across the studies, the S_r values
25 for LR were small (i.e., less than 0.84), most notably for treatments generating high mean LRs (5
26 or above) where the S_r was as small as 0.12. Overall, the S_R values ranged from 0.227 to 1.217.
27 Only three of the twenty-four treatment combinations over the study period resulted in S_R values
28 above 1.0 – the associated LRs for the three treatments ranged from 2.22 to 3.26. Antimicrobial
29 treatments with a LR of 4.5 or higher exhibited S_R of 0.561 or less. The statistical attributes
30 reported here for the draft Quantitative Method when used to test *P. aeruginosa*, *S. aureus*, and
31 *M. terrae* provide information for decision makers when considering the method as a candidate
32 regulatory procedure. The data and statistical analyses contained in this report are historical in
33 nature and provide useful baseline information for individuals conducting additional technical
34 review of the method. Based on the data, the Quantitative Method displays a statistical profile
35 consistent with other standard methods approved by standard-setting organizations where
36 method performance data are available.

37

38 **1. Introduction**

39

40 Cleaning and disinfection of environmental surfaces are important practices for reducing the
41 spread of public health pathogens in a wide range of clinical, household, institutional, veterinary,
42 commercial, and food production settings (Abreu et al., 2013; AHRQ, 2015; Alfa et al., 2015;
43 Boyce, 2016; Dancer, 2014; Donskey, 2013; Hota, 2004; Quinn et al., 2015; Rutala et al., 2013).
44 To ensure the performance of antimicrobial products in the field prior to sale and distribution,
45 regulatory authorities have established policies to document the effectiveness of antimicrobial

46 products according to their labeling. The availability of validated standardized laboratory methods
47 is essential to the regulatory process. Throughout the world, a variety of different methods are
48 recognized for the generation of efficacy data for antimicrobial products; however, to date, there
49 is no single method or platform for assessing product efficacy that can be used and accepted by all
50 countries. For example, in the United States (US), the regulatory oversight for antimicrobial
51 products is the responsibility of the Environmental Protection Agency's (EPA) Office of Chemical
52 Safety and Pollution Prevention (OCSPP), Office of Pesticide Programs (OPP). The statutory
53 authority for the registration of antimicrobial products falls under the Federal Insecticide,
54 Fungicide, and Rodenticide Act (FIFRA). In the US, antimicrobial pesticides bearing claims for
55 control of microorganisms on inanimate surfaces which are infectious to humans are considered
56 directly related to human health – these are known as public health antimicrobial products. Under
57 FIFRA, the registrant of an antimicrobial product with a public health claim is required to submit
58 efficacy data to EPA in support of the product's registration. Efficacy test guidelines, Series
59 810.2000–Product Performance Test Guidelines: OCSPP 810.2200 Disinfectants for Use on Hard
60 Surfaces-Efficacy Data Recommendations have been established by the OCSPP to inform the
61 manufacturer which test methodology is appropriate to support a specific efficacy claim (US EPA
62 OCSPP, 2018). The OPP Antimicrobials Division (AD) reviews the product efficacy data and if
63 the data meet the efficacy standards and all other requirements for registration are met, the product
64 is granted a registration and is issued an EPA registration number. An overview of EPA's
65 regulatory process for antimicrobial pesticides has been published (Tomasino et al., 2021)

66

67 The development, validation and use of new quantitative methodologies for testing the
68 effectiveness of antimicrobial products are necessary to meet the regulatory challenges associated

69 with an ever-changing marketplace, novel product claims, new infection control practices, and the
70 emergence of new clinical pathogens. As part of this effort, the US and other OECD (Organization
71 of Economic Co-operation and Development) member countries initiated an evaluation of a set
72 antimicrobial test methods for the purpose of international harmonization of test methods for
73 measuring the performance of antimicrobial products. The OECD is an intergovernmental
74 organization in which representatives of 34 industrialized countries in North and South America,
75 Europe and the Asia and Pacific region, as well as the European Commission, participate
76 collaboratively in response to international problems (OECD, 2018). Most of the OECD's work is
77 facilitated by more than 200 specialized committees and working groups composed of member
78 country delegates. In 2002, an international workshop of the US and OECD member countries
79 identified scientific and regulatory areas in need of harmonization for testing antimicrobial
80 products. From the 2002 workshop, a primary goal of selecting and validating a quantitative test
81 method to assess the activity of antimicrobial products for use on hard non-porous surfaces was
82 proposed. The methodology down selected for consideration is derived from an existing standard
83 method, ASTM E2197, the Standard Quantitative Disk Carrier Test Method (ASTM E2197, 2017).
84 The technical attributes of ASTM E2197 have been previously summarized (Springthorpe, 2005)
85 and investigated in two previous multi-laboratory studies (Parker et al. 2018). For the purpose of
86 this paper, the method will be referred to as the Quantitative Method. The Quantitative Method
87 retains the primary attributes of ASTM E2197; however, microbe-specific modifications and
88 additional areas of optimization were applied during our studies.

89
90 A summary of EPA's approach to method development and standardization has been published
91 (Tomasino, 2014) and the activities described in this paper are highly relevant to that process. For

92 background, the process for the development of OECD guidelines for testing chemicals is provided
93 in an OECD Guidance Document (OECD, 2009). The OECD Test Guideline Program provides a
94 structured consensus-based technical peer review process of a candidate method for an intended
95 purpose, the data requirements, generation and review of method validation data, and a transparent
96 approval process. In the early stages of the OECD-facilitated process, an *ad hoc* group of
97 international experts under the auspices of the OECD Task Force on Biocides was tasked with
98 overseeing the technical evaluation and direction of the project. Between 2008 and 2010, a series
99 of international ring trials (interlaboratory studies) were conducted to validate the proposed
100 method; the outcome of the ring trials was posted by the OECD (OECD, 2011). In 2011, the draft
101 method and the validation report were reviewed by the OECD Working Group of National
102 Coordinators (WNT) of the Test Guidelines Programme; the WNT is comprised of regulatory
103 representatives from the various OECD member countries. Upon review, the WNT recommended
104 several revisions to the method and additional data collection to further ascertain the performance
105 of the method across laboratories. Main areas where the method was revised included the use of
106 more stringent culture preparation practices, identification of control carrier count levels for a valid
107 test, inclusion of a reference standard, and enhancements to the microbe recovery process. In
108 response to the WNT's recommendations, four interlaboratory studies were performed in the US
109 from 2011 through 2013 to address proposed revisions and to further assess the statistical
110 performance of the revised method. The interlaboratory studies discussed in this report involve
111 tests of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Mycobacterium terrae*.

112

113 **2. Methods**

114

115 2.1 *Quantitative Method Overview*

116 The Quantitative Method uses 1 cm diameter disks (carriers) of brushed stainless steel as the
117 material to represent a hard, non-porous surface. Each disk receives 10 μL of microbial inoculum
118 (with a three-part organic and inorganic soil load) deposited in the center of each carrier. The
119 inoculum is dried and exposed to 50 μL of the liquid antimicrobial treatment being tested; control
120 carriers receive an equivalent volume of an innocuous fluid (e.g., phosphate buffered saline). The
121 exposure time (e.g., 5 min) is allowed to elapse; 10 mL neutralizer is then added to the vial to halt
122 the antimicrobial action. Each vial with the carrier is vortexed, serially diluted, and then filtered or
123 direct plated to recover viable microorganisms. Based on the difference between the mean \log_{10}
124 density values of the untreated control and treated carriers, a \log_{10} reduction (LR) in viable bacteria
125 is calculated. The LR value is used as the measure of product effectiveness, where higher LR
126 values are indicative of greater microbial kill.

127

128 2.2 *Frozen stock cultures*

129

130 Frozen stock cultures of *P. aeruginosa* (ATCC No. 15442) and *S. aureus* (ATCC No. 6538) were
131 prepared by rehydrating lyophilized cultures with approximately 1 mL tryptic soy broth (TSB) and
132 transferring the entire rehydrated mixture into 5 mL of TSB, mixing thoroughly and incubating at
133 $36\pm 1^\circ\text{C}$ for 24 ± 2 h. The growth was streak isolated onto tryptic soy agar (TSA), incubated at
134 $36\pm 1^\circ\text{C}$ for 24 ± 2 h, and several isolated colonies were collected and re-suspended in 1 mL of TSB.
135 Golden/yellow colonies were selected for *S. aureus*. Each of three colonial phenotypes was
136 selected for *P. aeruginosa*. The suspension (0.1 mL) was spread plated on 6-10 plates of TSA and
137 incubated for 18-24 h at $36\pm 1^\circ\text{C}$. Following the incubation, 5 mL sterile cryoprotectant (TSB with

138 15% v/v glycerol) were added to the surface of each plate. The growth was re-suspended in
139 cryoprotectant using a sterile spreader. The suspension from each plate was removed with a pipette,
140 pooled in a sterile vessel, and thoroughly mixed. Small aliquots of the harvested suspension were
141 transferred into cryovials and stored at -70°C.

142 Frozen stock cultures of *M. terrae* (ATCC No. 15755) were prepared by adding 1.0 mL of
143 Middlebrook 7H9 Broth with 10% (v/v) ADC enrichment (MADC) to a lyophilized culture and
144 transferring the entire rehydrated pellet back into 5 mL of MADC. After mixing, the suspension
145 (0.1 mL) was spread plated onto 6-10 plates of M7H9 or M7H11 agar and incubated for 20-22
146 days at 36±1°C. At the end of the incubation period, 5 mL of MADC was added to the surface of
147 each plate and re-suspended using a sterile spreader to gently scrape the agar surface. The
148 suspension was removed with a pipette, pooled, and mixed. While mixing continuously, small
149 aliquots of the harvested suspension were placed into separate cryovials and stored at -70°C. The
150 titer of the frozen stock was approximately 1×10⁹ CFU/mL.

151

152 2.3 Test cultures

153 For *S. aureus*, TSB was used to grow the test cultures. For *P. aeruginosa*, synthetic broth (SB) was
154 used for the generation of the test cultures in Study one; however, due to the inconsistent
155 commercial availability of SB, TSB was used in Study two. Test cultures were prepared by
156 defrosting a frozen stock culture and adding 0.1 mL of the culture to 10 mL of broth (SB or TSB
157 per the study) vortex-mixed, and incubated for 18-24 h at 36±1°C.

158 For *P. aeruginosa* cultures, visible pellicle was separated from the broth prior to harvest. The
159 culture was discarded if the pellicle was disrupted and showed fragments in the broth. Using a

160 pipette, the remaining broth culture was withdrawn, avoiding any sediment on the bottom of the
161 tube, and transferred into a 15 mL conical tube. For *S. aureus*, the cultures were briefly vortexed
162 and transferred to a 15 mL conical tube. The culture was centrifuged at ~5,000 gN for 20±5 min
163 and the supernatant was removed without disrupting the pellet. The pellet was re-suspended in a
164 maximum of 10 mL PBS. Further dilution was allowed prior to the addition of the soil load to meet
165 the prescribed control carrier count levels. This culture was used to prepare the final test suspension
166 which included the soil load – see sections 2.4 and 2.5.

167 For *M. terrae*, the test culture was initially (Study three) grown statically (without agitation) by
168 adding 1 mL thawed stock culture to a flask of 100 mL MADC and incubating at 36±1°C for 20-
169 22 days. For Study four, 1 mL of thawed frozen stock culture was added to a flask of 100 mL
170 MADC, sealed with foil and incubated at 36±1°C for 7-10 days under agitation at 150 rpm.
171 Following incubation, 25 mL portions of the MADC broth culture were aliquoted into each of 2-
172 50 mL conical tubes and centrifuged at ~10,000 gN for 20±5 min. The supernatant was removed,
173 and the pellet was re-suspended in 25 mL sterile de-ionized (DI) water and centrifuged a second
174 time. The pellets were re-suspended in a total of 5 mL sterile DI water, placed in a sterile glass
175 tissue grinder, and homogenized. The culture was transferred to a small bottle (e.g., bijou bottle)
176 with glass beads, capped, and vortexed for 5 min. The concentration of the final culture was
177 adjusted with sterile DI water to achieve control carrier counts within the prescribed range for each
178 study.

179

180 *2.4 Three-part soil load*

181 Prior to carrier inoculation, a soil load, with organic and inorganic components, was incorporated
182 in the test suspension using the following three stocks: a) bovine serum albumin (BSA) prepared
183 by adding 0.5 g BSA to 10 mL of PBS, mixed and filter sterilized, b) yeast extract prepared by
184 adding 0.5 g yeast extract to 10 mL of PBS, mixed, and filter sterilized, and c) mucin prepared by
185 adding 0.04 g mucin to 10 mL of PBS, mixed and sterilized by autoclaving (15 min at 121°C).
186 Each stock was stored at $-20\pm 2^{\circ}\text{C}$.

187 *2.5 Final test suspension*

188 For each test day, a minimum of 500 μL of the final test suspension was prepared by combining
189 the following components: 25 μL BSA stock, 35 μL yeast extract stock, 100 μL mucin stock, and
190 340 μL of the test suspension. The final test suspension (held at $22\pm 2^{\circ}\text{C}$), was used to inoculate
191 carriers within 30 min of preparation.

192 *2.6 Treatment diluent – 375 ppm hard water*

193 For the preparation of antimicrobial treatments requiring dilution, the test substance was diluted
194 in 375 ppm hard water. Solution A was prepared by dissolving 19.84 g anhydrous MgCl_2 (or 42.36
195 g $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$) and 46.24 g anhydrous CaCl_2 in DI water, and diluting to 1 L. Solution B was
196 prepared by dissolving 35.02 g NaHCO_3 in water, and diluting to 1 L. Solutions A and B were
197 filter sterilized and stored under refrigeration. Per 1 L of 375 ppm hard water, 6.0 mL of solution
198 A and 8.0 mL of solution B were added to 600 mL DI water, mixed, and brought to a 1L volume
199 with DI water. The target pH was 7.0 ± 0.2 . On the day of the test, the hardness of the water was
200 verified using a water hardness test kit or other suitable titration method. The target hardness
201 expressed as mg/L calcium carbonate (CaCO_3) was 375 mg/L $\pm 5\%$ (337-394 mg/L).

202 *2.7 Carriers*

203 One cm diameter disks made from 0.7 mm thick sheets of brushed and magnetized stainless steel
204 (AISI #430) were utilized (e.g., Pegen Industries, part #430-107). Carriers were prepared (by the
205 manufacturer) to achieve a number 4 finish (polished), soaked in a mild acid bath to remove any
206 impurities and accumulated debris from the carrier surface, and tumbled with ceramic chips and a
207 cleanser to remove the punching burrs from the edges of the disks. Prior to use, the brushed surface
208 of the carriers was visually checked for abnormalities (e.g., rust, chipping, deep striations) and
209 discarded if observed. Carriers were soaked in a detergent solution for 2-4 h to degrease them and
210 then rinsed thoroughly in DI water. Approximately 20 clean dry carriers were placed on a piece of
211 filter paper inside a glass Petri dish with the lid applied and sterilized. Sterile carriers were
212 transferred topside up to sterile Petri dishes (plastic) without filter paper for inoculation. Carriers
213 were single use only.

214 *2.8 Inoculation and drying of carriers*

215 Carriers were placed in Petri plates prior to inoculation. Immediately prior to carrier inoculation,
216 the final test suspension was briefly vortexed and then re-vortexed periodically during the
217 inoculation process. Depending on the study, 3-4 untreated control carriers and 3-4 treated carriers
218 (per test substance treatment) were used. Ten microliters of the final test suspension were applied
219 to the center of each carrier with a calibrated positive displacement pipette (with a 10 μ L tip).
220 Inoculated carriers where the final test suspension leaked over the edge were discarded. The Petri
221 dish with the inoculated carriers was transferred to a desiccation unit, lid removed, unit sealed with
222 vacuum applied and maintained at 0.068 to 0.085 MPa at $22\pm 2^\circ\text{C}$ for 60 ± 10 min. Dried, inoculated
223 carriers were held at room temperature and used for testing within one hour after drying.

224 *2.9 Exposure of the inoculum to the test substance or PBS (control)*

225 Using sterile forceps, each dried carrier was transferred (inoculated side up) into a flat-bottom vial
226 and capped. In timed, staggered intervals, 50 μ L of the test substance (equilibrated to $22\pm 2^\circ\text{C}$) or
227 control substance (PBS) was deposited with a micropipette over the dried inoculum on each test
228 carrier, ensuring complete coverage. The pipette tip was not allowed to contact the carrier surface.
229 The vials were left uncapped and test carriers held at $22\pm 2^\circ\text{C}$ for 5 min. Any carrier where the test
230 substance leaked off was not used and was replaced with new carrier and vial.

231

232 *2.10 Neutralization of test substance*

233 At the end of the 5 min exposure period, 10 mL of neutralizer was added to each vial in the order
234 treated, including controls. The neutralized solution with the carrier was deemed the 10^0 dilution
235 for the quantification step. Each vial was briefly vortexed following the addition of the
236 neutralizer. Following the addition of neutralizer across the entire set of carriers, each vial was
237 vortexed again for 30 s at high speed to recover the surviving microorganisms. See section 2.12.6
238 for the neutralization confirmation protocol.

239

240 *2.11 Dilution and recovery*

241 Using the 10.05 mL neutralized suspension, serial 10-fold dilutions were initiated within 30 min
242 of the addition of the neutralizer. For calculation purposes, a value of 10.00 mL was utilized for
243 the neutralized suspension. The liquids were filtered using pre-wetted (with 10 mL PBS) $0.2\ \mu\text{m}$
244 polyethersulfone (PES) membrane filters for *S. aureus* and *P. aeruginosa* and $0.45\ \mu\text{m}$ PES
245 membrane filters for *M. terrae*; filtration was initiated within 30 min of preparing the dilutions.
246 Vacuum was applied to facilitate filtering. The entire contents of each treatment vial (with the

247 treated carrier) and dilution tube (e.g., 10^{-1}) were filtered. For the vial, a magnet was used to hold
248 the carrier in place while dispensing the liquid onto the membrane. The vial was rinsed with ~20
249 mL of PBS and briefly vortexed, while keeping magnet in place, poured into the same filter unit.
250 For dilution tubes, each tube was rinsed once with ~10 mL of PBS, vortex-mixed, and poured into
251 filter unit. With the vacuum on, the inside surface of each filtration unit was rinsed with an
252 additional ~40 mL PBS. The membrane filter was placed on the appropriate recovery medium;
253 TSA was used for *S. aureus* and *P. aeruginosa*, and M7H11 was used for *M. terrae*.

254 For the control carriers, contents of the vial were serially diluted and filtered (Study one only) or
255 direct plated (100 μ L) in duplicate (Study two) on the appropriate recovery medium. For *S. aureus*
256 and *P. aeruginosa*, plates were incubated at $36\pm 1^\circ\text{C}$ for 48 ± 4 h. For *M. terrae*, plates were
257 incubated at $36\pm 1^\circ\text{C}$ for 17-21 days.

258 The number of colonies was recorded at the end of the incubation period. Counts up to 200 and
259 300 were used in the calculations for filtered and direct plated aliquots, respectively. The colony
260 forming units (CFUs) per carrier were calculated by taking the weighted average across all
261 countable dilutions (Hamilton & Parker 2010) and then converted to log density by taking the \log_{10}
262 of the density (CFUs per carrier). The mean \log_{10} densities across individual sets of treated and
263 control carriers were calculated. The \log_{10} reduction (LR) for each test was calculated as the mean
264 \log_{10} density for the control carriers in that test (*TestLD*) minus the mean \log_{10} density for treated
265 carriers in that test.

266

267 2.12 Interlaboratory evaluations

268 2.12.1 Basic study principles

269 The overarching goal of the interlaboratory investigations was to determine the statistical profile
270 of the draft Quantitative Method for testing liquid products on a hard non-porous surface, with
271 targeted revisions, using a standardized study protocol. The conduct of these studies was
272 consistent with EPA method validation guidelines (U.S. EPA, 2016), standard setting
273 organizations such as AOAC International (AOAC International, 2016), ASTM International
274 (ASTM standard E691, 2013), and recommendations provided by Hamilton et al., 2013. Each
275 laboratory designated a technical team to conduct the study and was asked to practice the method
276 prior to launching the study to gain proficiency. The technicians were asked to evaluate a set of
277 liquid antimicrobial test substances in a blinded, randomized, and replicated fashion. Study
278 documentation, including peer review, was consistent with Good Laboratory Practice Standards
279 (US EPA, 1997).

280 The primary response variables were the log₁₀-transformed carrier counts and the resulting LR
281 outcomes as the measurement of treatment effectiveness. As an integral part of the test design, a
282 set of test substances with the potential to provide a range of LRs was evaluated to simulate the
283 challenges of the real-world uses. The treatments were evaluated in a blinded, randomized fashion.
284 Three replications (separate test days) were conducted for each test substance.

285 The studies allowed for the assessment of four key method performance indicators: 1) consistent
286 control carrier counts (resemblance), 2) the ability to produce repeatable LRs within the same lab
287 (repeatability), 3) the ability to produce reproducible LRs among labs (reproducibility), and 4) the
288 capacity of the method to differentiate the antimicrobial efficacy of two levels of a test substance
289 with presumed high and low log reduction outcomes (responsiveness).

290 *2.12.2 Standardized test conditions*

291 Three test conditions were employed for the evaluation of each antimicrobial and reference

292 standard treatment: 1) incorporation of a three-part soil load into the final test suspension prior to
293 carrier inoculation, 2) use of 375 ppm hard water as the treatment diluent (when necessary), and
294 3) an exposure time of 5 min.

295

296 *2.12.3 Antimicrobial test substances – treatments*

297 The test substances were derived from antimicrobial formulations with active ingredients relevant
298 to the marketplace. The treatments were not evaluated to confirm the label claims of a product.
299 The treatments were prescreened in advance by a single laboratory to presumptively provide a
300 range of effectiveness (i.e., range of LRs). Each lab received a sub-sample of the same production
301 batch of each test substance. Treatments were provided as “ready to use” or as dilutable
302 concentrates. The neutralizer solutions were confirmed as effective in advance of testing per the
303 methodology provided in section 2.12.6.

304

305 *2.12.4 Sodium hypochlorite-based reference standard treatments*

306 For the purpose of developing a reference standard and to measure method responsiveness, tests
307 of certified laboratory grade sodium hypochlorite (NaOCl) were incorporated into the study
308 design. Two concentrations of NaOCl were tested per microbe. Each laboratory was asked to
309 prepare the test solutions and to verify the concentrations of available chlorine prior to conducting
310 the tests using a Hach test kit, or comparable analysis. The two NaOCl treatments were tested side-
311 by-side on the same test day with presumed high and low log reduction outcomes. The neutralizer
312 solution was letheen broth with 0.1% (w/v) sodium thiosulfate (Na₂S₂O₃).

313

314 *2.12.5 Control carrier counts*

315 Quantification of the inoculum level on the untreated control carriers post-drying is an essential
316 component to the method. An acceptable range of mean log density of the control carriers (i.e.,
317 *TestLD*) was established for each study. The number of control carriers ranged from three to four
318 depending on the study. One set of control carriers was used to represent one or more treatments
319 on any given test day. Individual carrier counts or mean control carrier count values slightly
320 above or below the acceptable range were permissible upon discussion with the study director.

321 *2.12.6 Neutralization confirmation protocol*

322 The effectiveness of the neutralizer solution was determined in advance of each study using a
323 quantitative assay. In triplicate, the test substance (50 μ L) and neutralizer (10 mL) were vortex-
324 mixed together for 10 s, 10 μ L diluted final test suspension (20-200 CFU per vial) were added to
325 each mixed solution, and held for 10 min at room temperature. The entire contents of each vial
326 were filtered, and the test microbe enumerated. The titer of the final test suspension and the
327 toxicity of the neutralizer were determined for comparative purposes; 10 mL volumes of PBS
328 (for the titer) and the specified neutralizer were inoculated and enumerated per the procedure for
329 the neutralizer effectiveness component of the assay. To be deemed an acceptable neutralizer,
330 the recovered number of bacteria in the neutralizer effectiveness and neutralizer toxicity
331 treatments was at least 50% of the titer control (equivalent to a difference of 0.3 on the log₁₀-
332 scale). Neutralizers utilized in these studies were letheen broth, letheen broth with 0.1% (w/v)
333 sodium thiosulfate, and PBS with 0.1% (v/v) polysorbate 80 and 0.1% (w/v) sodium thiosulfate.

334 *2.13 Interlaboratory studies involving S. aureus and P. aeruginosa*

335 *2.13.1 Study one*

336 Nine laboratories evaluated four antimicrobial treatments: phenolic (0.074%), hydrogen peroxide
337 (0.5%), citric acid (0.6%), and quaternary ammonium compound (0.066%), and two NaOCl
338 reference standard treatments. NaOCl concentrations of 2000 ppm and 500 ppm were tested
339 against *S. aureus*. For *P. aeruginosa*, 2000 ppm and 250 ppm NaOCl were tested. Lethen broth
340 was used as the neutralizer for the four antimicrobial treatments. Three replicate tests on
341 independent days were conducted for each microbe and treatment combination. The target
342 control carrier count level was 4.5 to 5.5 log₁₀(CFU/carrier). Four untreated control carriers and
343 three treated carriers (per antimicrobial test substance) were utilized. In this study, SB was used
344 to generate the *P. aeruginosa* test cultures instead of TSB, and the control and treated carrier
345 suspensions were filtered for recovery.

346

347 2.13.2 Study two

348 Following the completion of interlaboratory Study one, refinements to the method were
349 introduced and a second study was conducted. The revised method was resubmitted for
350 evaluation by seven laboratories. The main revisions included: 1) reducing the number of control
351 carriers from four to three, 2) use of TSB instead of SB to generate the *P. aeruginosa* test
352 suspensions, 3) increasing the target control counts to 5.0 to 6.0 log₁₀(CFU/carrier), and 4) direct
353 plating (in duplicate) of control carrier dilutions onto TSA. The treatments were the quaternary
354 ammonium formulation tested in Study one and two NaOCl treatments. The low efficacy NaOCl
355 treatment for *P. aeruginosa* was adjusted lower to 200 ppm. Three replicate tests on independent
356 days were conducted for each microbe and treatment combination.

357 2.14 Interlaboratory studies with *M. terrae*

358 Two interlaboratory studies were conducted with *M. terrae* as the test microbe.

359 *2.14.1 Study three*

360 In the first study, seven laboratories evaluated four antimicrobial treatments, phenol (0.074%),
361 hydrogen peroxide (4.4%) and peroxyacetic acid (0.23%), citric acid (0.60%), quaternary
362 ammonium compound (0.21%), and a set of NaOCl treatments (2000 ppm and 500 ppm). The
363 target control carrier count level was 4.5 to 5.5 log₁₀(CFU/carrier). Three replicate tests on
364 independent days were conducted for each treatment.

365 *2.14.2 Study four*

366 Participants in Study three indicated that the growth of the static culture was not homogeneous
367 and often appeared pellicle-like in the flask. To resolve the issue, revisions were made to the
368 preparation of the test suspension. For Study four, agitation of the MADC broth culture was used
369 during incubation, followed by centrifugation and a homogenization step (see section 2.3 – *Test*
370 *Cultures*). Also, the control carrier count range was adjusted to 5.0 to 6.0 logs CFU/carrier. To
371 verify the changes, control carrier count data were generated over three replicate tests on
372 independent days. No antimicrobial treatments were evaluated in this study.

373

374 *2.15 Statistical methods*

375 In all 4 studies, the mean of the log-transformed density of microbes on the untreated control
376 carrier counts and the associated LRs were the primary responses.

377 *2.15.1 Repeatability and Reproducibility*

378 The main outputs of the statistical analysis are the *repeatability* of these responses from
379 experiment to experiment in an individual laboratory, and the *reproducibility* of the responses
380 across multiple laboratories. These attributes were quantified by a repeatability SD (S_r) and a
381 reproducibility SD (S_R) respectively. Both these SDs are results from analyzing the *TestLDs* and
382 LRs (for each agent) in each multi-laboratory study separately by a linear mixed effects model
383 (LMM) with a random effect for laboratory (Hamilton et al. 2013, Pinheiro and Bates 2002).
384 Each analysis provided the repeatability variance (S_r^2), and also the among-laboratory variance
385 (S_{lab}^2). The reproducibility SD was then $S_R = [S_r^2 + S_{lab}^2]^{1/2}$. Residual plots were used to
386 investigate potential outliers, confirm the homogeneous variance assumption, and to assess that
387 the residuals approximately followed a normal distribution (Hamilton et al. 2013). These
388 calculations, notation, and terminology are consistent with guidelines published by ASTM E691
389 and AOAC (2016). Calculations were performed using the software R (R Core Team 2017)
390 package *nlme* (Pinheiro 2017). Explicit R code used for the analysis of a multi-laboratory data
391 set is available on-line (Parker and Hamilton 2013).

392

393 2.15.2 Responsiveness

394 Responsiveness of the method to the differing efficacy levels of NaOCl was assessed by testing
395 whether there was a difference in the mean LRs associated with the two efficacy levels. In each
396 multi-laboratory study, because the two NaOCl treatments were always tested side-by-side on the
397 same day, responsiveness was assessed by fitting an LMM to the difference in LRs observed on
398 each test day.

399

400 3. Results

401 3.1 Interlaboratory test data

402 3.1.1 Interlaboratory Study one – *S. aureus* and *P. aeruginosa*

403 A total of 113 individual tests (tests involving two NaOCl solutions and four antimicrobial test
404 substances) across both microbes were conducted by 9 laboratories. A summary of the control
405 carrier count data (*TestLDs*) is provided in Table 1 (see also Figures S1-S2 in the Supplementary
406 Material). The specified control carrier count level was consistently achieved and ranged from 4.5
407 to 5.7. Seven of the 113 tests resulted in *TestLDs* values slightly above 5.5; however, the data were
408 deemed valid by the study director and were included in the analysis. The pooled *TestLDs* for the
409 NaOCl tests and the four antimicrobial treatment tests show mean *TestLDs* of 5.07 and 5.03 for *P.*
410 *aeruginosa* and *S. aureus*, respectively. The repeatability (S_r) and reproducibility (S_R) values were
411 less than 0.3 for both microbes – the lowest was the S_r for *S. aureus* at 0.172 and the highest was
412 the S_R for *P. aeruginosa* at 0.288.

413 The six antimicrobial treatments (two NaOCl treatments and four other antimicrobial test
414 substances per microbe) provided a broad range of mean LR values ranging from 3.17 to 5.40 for
415 *P. aeruginosa* tests and 1.51 to 5.28 for *S. aureus* tests (Table 2, Figures 1-2). Using the side-by-
416 side test data for assessing the presumed low and high efficacy solutions of NaOCl, the method
417 was responsive to the differing efficacy levels. In other words, statistically significant differences
418 in the mean LR (2.12 for *P. aeruginosa* and 3.83 for *S. aureus*) were exhibited for the two NaOCl
419 treatments per microbe (p-value < 0.001). The 2000 ppm NaOCl treatment often resulted in no
420 recovery of viable bacteria and the resulting S_r and S_R ranged from 0.162 to 0.276. Higher
421 variability occurred with the 250 ppm and 500 ppm NaOCl concentrations; however, the S_r and S_R
422 were less than 1.0.

423 The hydrogen peroxide and citric acid-based treatments consistently generated high LRs across
424 both microbes with associated S_r and $S_R \leq 0.390$. The phenolic treatment exhibited mean LRs of
425 5.33 and 4.50 when tested against *P. aeruginosa* and *S. aureus*, respectively. Similar S_r (e.g., 0.334
426 for *P. aeruginosa* and 0.429 for *S. aureus*) and S_R (e.g., 0.490 for *P. aeruginosa* and 0.561 for *S.*
427 *aureus*) were observed for the tests of the phenolic. The quaternary ammonium treatment resulted
428 in comparatively lower LR values for both microbes ranging from 3.26 for *P. aeruginosa* to 3.68
429 for *S. aureus*. The associated S_R for the quaternary ammonium treatment was higher (1.217 for *P.*
430 *aeruginosa* and 0.852 for *S. aureus*) compared to the other treatments.

431 3.1.2 Study two – *S. aureus* and *P. aeruginosa*

432 In this method optimization study, a total of 38 individual tests were conducted by 7 labs. Two
433 NaOCl solutions and one antimicrobial test substance per microbe were evaluated. Compared to
434 Study one, the *TestLDs* for both microbes were approximately 0.5 logs higher (Table 1, see also
435 Figure S3 in the Supplementary Material). The increase in the *TestLDs* was anticipated per the
436 modification in the study protocol for a 0.5 log increase in the target range of *TestLDs*. Mean
437 *TestLDs* of 5.45 and 5.67 were recorded for *P. aeruginosa* and *S. aureus*, respectively. S_r and S_R
438 were similar to those observed in Study one; the highest level was the S_R for *P. aeruginosa* at
439 0.346. Thus, good resemblance of the control carrier counts was confirmed using the method
440 modifications employed to optimize the test procedure.

441 The NaOCl treatments provided a 3 to 4 log difference in mean LR (Table 2; see also Figure 3).
442 The 2000 ppm NaOCl treatment resulted in a high level of kill for both microbes, mainly resulting
443 in no viable cells recovered. The 200 ppm concentration of NaOCl provided a mean LR of 2.69
444 for *P. aeruginosa*. *S. aureus* exhibited a mean LR of 1.84 when exposed to the 500 ppm NaOCl.
445 The S_r values for each NaOCl treatment ranged from 0.115 (2000 ppm NaOCl treatment for *S.*

446 *aureus*) to 0.397 (200 ppm NaOCl treatment for *P. aeruginosa*). The S_R ranged from 1.141 for *P.*
447 *aeruginosa* when tested against the 200 ppm NaOCl to 0.234 for the 2000 ppm NaOCl treatment
448 tested against *S. aureus*. The mean difference in LR for the two NaOCl treatments was 3.0 for *P.*
449 *aeruginosa* tests (p-value < 0.001) and 4.1 for *S. aureus* tests (p-value < 0.001), indicating good
450 responsiveness to the differing concentrations of NaOCl for both microbes.

451 The mean LR for the quaternary ammonium-based treatment (also tested in Study one) ranged
452 from 1.36 for *P. aeruginosa* to 2.98 for *S. aureus* (Table 2; see also Figure 3). Across both test
453 microbes, the variability in the data was similar for quaternary ammonium treatment (S_r of 0.537
454 to 0.589 and S_R of 0.718 to 0.798).

455 3.1.3 Study three – *M. terrae*

456 Data from 33 independent tests were generated by four labs. A summary of the *TestLD* for *M.*
457 *terrae* is presented in Table 1 (see also Figure S4 in the Supplementary Material). A mean *TestLD*
458 of 5.09 was exhibited with a S_r of 0.263 and S_R of 0.329 which are indicators of good resemblance
459 of the carrier count data.

460 Across the laboratories, the 500 and 2000 ppm NaOCl treatments provided LRs of 0.97 and 3.28,
461 respectively (Table 2, Figure 4). The S_r of the LR data was 0.247 (500 ppm) and 0.392 (2000 ppm).
462 The 2000 ppm NaOCl treatments exhibited S_R of 0.947 compared to 0.272 for the 500 ppm NaOCl
463 treatment (Table 2). A mean difference in LR between treatments of 2.3 (p-value <0.001) was
464 exhibited between the two NaOCl treatments. Hence, the method was responsive to the two
465 NaOCl treatments against *M. terrae*.

466 The LRs of *M. terrae* ranged from 1.53 (citric acid) to 5.21 (hydrogen peroxide) – see Table 2 and
467 Figure 4. The S_r was 0.257 for tests of citric acid to 0.452 for tests of phenol (Table 2). Tests of the

468 phenol and the quaternary ammonium treatments exhibiting S_R of 1.175 and 0.987, respectively
 469 (Table 2).

470

471 3.1.4 Interlaboratory study number four – optimization of the *M. terrae* test culture

472 Concerns were expressed by the participants in Study three that *M. terrae* grown in static liquid
 473 cultures was difficult to standardize and use of agitation during incubation may be more
 474 appropriate. Thus, another study was conducted to optimize the growth conditions of the test
 475 microbe. An increase in the *TestLD* to 5.38 from 5.09 was noted for Study four which incorporated
 476 the modified suspension methodology and called for a target control count level of 5.0 to 6.0 logs
 477 per carrier. Furthermore, S_r and S_R were smaller than in Study three thus verifying that the
 478 optimization of the protocol was successful (Table 1; see also Figure S5 in the Supplementary
 479 Material).

480 **Table 1.** Analysis of log densities of the untreated controls from Studies one through four.

Interlaboratory		Num.	Num.	Mean	SEM ¹		
Study	Microbe	Labs	Tests	<i>TestLD</i>	<i>TestLD</i>	S_r	S_R
Study one (2012)	<i>P. aeruginosa</i>	9	58	5.07	0.065	0.232	0.288
	<i>S. aureus</i>	9	55	5.03	0.075	0.172	0.274
Study two (2014)	<i>P. aeruginosa</i>	7	19	5.45	0.114	0.222	0.346
	<i>S. aureus</i>	7	19	5.67	0.079	0.163	0.244
Study three							
(2013)	<i>M. terrae</i>	6	33	5.09	0.092	0.263	0.329
Study four ²	<i>M. terrae</i>			5.38		0.235	0.324

(2014)

4

11

0.132

481 ¹SEM: standard error of the mean *TestLD* for the controls

482 ²Study included control carrier count evaluation only.

483

484 **Table 2.** Mean log reduction values and associated repeatability and reproducibility standard
485 deviations for the OECD Quantitative Method as evaluated in interlaboratory studies. The numbers
486 of labs and experiments are the same as reported in Table 1 except for Study three where the
487 NaOCl treatments were evaluated by 17 tests, and the other treatments by 16 tests, in 6 laboratories.

Study	Microbe	Treatment	Mean LR	SEM LR*	S _r	S _R
		250 ppm NaOCl	3.17	0.278	0.340	0.879
		2000 ppm NaOCl	5.29	0.076	0.192	0.276
		Phenolic	5.33	0.136	0.334	0.490
		Hydrogen peroxide	5.40	0.098	0.315	0.390
	<i>P. aeruginosa</i>	Citric acid	5.39	0.099	0.248	0.360
Study one (2012)		Quaternary ammonium	3.26	0.333	0.843	1.217
		500 ppm NaOCl	1.51	0.144	0.230	0.472
		2000 ppm NaOCl	5.34	0.062	0.162	0.227
		Phenol	4.50	0.146	0.429	0.561
	<i>S. aureus</i>	Hydrogen peroxide	5.28	0.102	0.157	0.331
		Citric acid	5.23	0.095	0.271	0.362
		Quaternary ammonium	3.68	0.261	0.407	0.852

Study two (2014)	<i>P. aeruginosa</i>	200 ppm NaOCl	2.69	0.416	0.397	1.141
		2000 ppm NaOCl	5.71	0.145	0.258	0.431
		Quaternary ammonium	1.36	0.208	0.589	0.718
	<i>S. aureus</i>	500 ppm NaOCl	1.84	0.243	0.175	0.655
		2000 ppm NaOCl	5.95	0.082	0.115	0.234
		Quaternary ammonium	2.98	0.257	0.537	0.798
Study three (2013)	<i>M. terrae</i>	500 ppm NaOCl	0.97	0.757	0.247	0.272
		2000 ppm NaOCl	3.28	0.365	0.392	0.947
		Phenol	2.22	0.457	0.452	1.175
		Hydrogen peroxide	5.21	0.113	0.400	0.419
		Citric acid	1.53	0.357	0.257	0.898
		Quaternary ammonium	2.30	0.370	0.494	0.987

488 * SEM: standard error of the mean log reduction

489

490 **4. Discussion**

491 Four interlaboratory studies were used to develop a statistical profile of an optimized version of
492 the draft Quantitative Method. The wide range of efficacy of the antimicrobial treatments
493 evaluated provided a wide range of mean LRs as well as an assessment of repeatability of the LRs
494 across experiments (S_r) and the reproducibility of the LRs across labs (S_R) – see Table 2. In studies
495 one, two and three, three distinct microbes were tested against relevant antimicrobial test
496 substances. In addition, the use of NaOCl solutions in the test design provided three functions, first
497 as a relevant active ingredient in the disinfectant marketplace; second, for use as a potential

498 reference standard material for the development of proficiency exercises; and third for verifying
499 the responsiveness of the test method.

500 Here the authors have identified four main areas of method performance: 1) resemblance of
501 untreated control carriers, 2) S_r of tests within a single laboratory, 3) S_R of tests between
502 laboratories, and 4) responsiveness of the method to changes in presumed treatment efficacy. A
503 quantitative method may be described as repeatable if several independent tests in the same
504 laboratory of the same antimicrobial test substance produce comparable *TestLDs* and LRs. The
505 method is reproducible if several independent tests in different laboratories of the same
506 antimicrobial test substance produce comparable *TestLDs* and LRs. Thus, small S_r and S_R of the
507 *TestLDs* and the LRs are highly desirable and indicative of acceptable method performance. Due
508 to the additional sources of variability, the laboratory-to-laboratory variability (S_R) is expected to
509 be higher than the variability within a single laboratory (S_r); this was observed across the studies
510 reported here. Ultimately, acceptable standard methods will be used by multiple laboratories, thus
511 the S_R level is the primary measure of variability of interest.

512 Good resemblance of control carrier counts is an essential property of a reliable quantitative
513 microbiological assay for testing the efficacy of disinfectants. Although some variability will
514 always exist in microbial assays, the use of the method's standardized procedures for the
515 preparation of the microbial test cultures, carrier inoculation process, management of the
516 inoculated carriers and microbe recovery ensure the generation of consistent *TestLDs*. Further, the
517 acceptance criterion for meeting the target *TestLDs* provides assurance that a test is valid. The
518 level of resemblance of the *TestLDs* accounts for the day-to-day variability associated with many
519 factors: the final test cultures, environmental conditions affecting the rate of drying, loss of
520 viability while drying, inoculum removal, and recovery. The small variability of *TestLDs* exhibited

521 by the Quantitative Method, as measured by S_r and S_R for the *TestLDs*, is a strong indicator of good
522 resemblance. As the acceptable range for *TestLD* was increased from 4.5-5.5 (in Study one) to 5.0-
523 6.0 $\log_{10}(\text{CFU}/\text{carrier})$ (in Study two), the *TestLD* for each test microbe exhibited comparable
524 levels of variability. Among the test microbes evaluated, *S. aureus* control carrier count data
525 exhibited the smallest S_r (ranging from 0.16 to 0.17) and S_R (ranging 0.24 to 0.27). The
526 resemblance S_r and S_R for *P. aeruginosa* and *M. terrae* control carriers were slightly higher than
527 *S. aureus*, but small with a maximum of 0.346 (the S_R for *P. aeruginosa* in Study two).

528 Across the studies, the S_r values for LR were small (i.e., less than 0.84), most notably for treatments
529 generating high mean LRs (5 or above) where the S_r was as small as 0.12. This outcome is
530 indicative of a repeatable method. Only three of the twenty-four treatment combinations over the
531 study period resulted in S_R values above 1.0 – the associated LR for the three treatments ranged
532 from 2.22 to 3.26. Antimicrobial treatments with a LR of 4.5 or higher exhibited S_R of 0.561 or
533 less. The S_R values ranged from 0.227 (see Study one, 2000 ppm NaOCl treatment for *S. aureus*)
534 to 1.217 (see study one, quaternary ammonium treatment for *P. aeruginosa*). Data from Study
535 two which implemented targeted method optimizations resulted in S_R ranging from 0.234 for the
536 2000 ppm NaOCl treatment for *S. aureus* to 1.141 for the 200 ppm NaOCl treatment for *P.*
537 *aeruginosa*. Also, in Study two, the S_R for the quaternary ammonium treatment for *S. aureus* and
538 *P. aeruginosa* were 0.798 and 0.781, respectively.

539

540 Based on differences in the LR values generated from the side-by-side testing of the NaOCl
541 treatments with weak and strong activity, the method was shown to be responsive to changes in
542 the NaOCl concentration for each test microbe. The use of reagent grade (laboratory grade) NaOCl
543 may serve as a standardized test chemical for training and proficiency testing and may serve as an

544 internal control to verify the quality of the test system on a day-to-day basis. In practice, other
545 active ingredients with documented levels of LR may also be used as an internal reference
546 standard; however, their efficacy profile should be verified by multiple laboratories in advance of
547 use.

548 Although standard setting organizations such as AOAC International and ASTM International
549 have not established formal guidance on acceptable levels of variability for quantitative methods,
550 the literature and several examples of approved standard methods may be used for comparative
551 purposes. Based on a review of the historical literature of suspension and dried surface tests, Tilt
552 and Hamilton provide an assessment that a S_r less than 1.0 and a S_R less than 1.5 should be
553 considered acceptable in terms of method performance (Tilt et al., 1999). Here we provide three
554 explicit examples. First, data to support the validation of the AOAC Three Step Method (AOAC
555 method 2008.05, 2008), a quantitative procedure for testing sporicidal chemicals against spores of
556 *Bacillus subtilis*, were generated from an eight-laboratory study (Tomasino et al., 2008). In the
557 study, the TSM control carriers exhibited S_r and S_R of 0.15 and 0.27, respectively. The resulting
558 LR for the TSM's treated carriers exhibited S_r ranging 0.17 to 0.72 and S_R 0.34 to 1.43. The TSM
559 is currently recognized by the EPA as an acceptable test method to support sporicidal product
560 claims against spores of *B. anthracis*. In the second example, data from an eight-laboratory study
561 were used to support the MBEC™ Physiology & Genetics Assay as an ASTM standard (ASTM
562 E2799-17, 2017; Parker et al., 2014) for measuring disinfectant efficacy against *P. aeruginosa*
563 biofilm. The S_r and S_R for the untreated controls for the MBEC™ method were 0.33 and 0.67,
564 respectively. The LR associated with the disinfectant treatments tested with the MBEC™ method
565 exhibited S_r levels ranging from 0.22 to 1.61, and S_R levels of 0.27 to 1.70. Our third and last
566 comparative example is the qualitative AOAC Use-dilution Method (AOAC Method 955.15, 2012;

567 AOAC Method 964.02, 2012) that was assessed in a five-laboratory collaborative study. The LRs
568 exhibited S_r of 0.15 to 0.33 and S_R of 0.32 to 0.55 in tests involving *S. aureus* and *P. aeruginosa*
569 (Tomasino et al., 2012). In the same study, the control carriers exhibited small S_r (range of 0.16 to
570 0.25) and S_R (range of 0.30 to 0.38).

571 **5. Conclusions**

572 In 2013, the data provided in this report were used to support the approval of an OECD Guidance
573 Document on Quantitative Methods for Evaluating the Activity of Microbicides used on Hard
574 Non-Porous Surfaces by the WNT (OECD, 2013); however, additional peer review is ongoing in
575 the US to further standardize the method. Furthermore, the data and statistical analyses contained
576 in this report are historical in nature and useful baseline information for individuals conducting
577 additional technical review of the method.

578

579 The statistical attributes reported here for the draft Quantitative Method when used to test *P.*
580 *aeruginosa*, *S. aureus*, and *M. terrae* provide information for decision makers when considering
581 the method as a candidate regulatory procedure. Based on the data, the Quantitative Method
582 displays a statistical profile consistent with other standard methods approved by standard-setting
583 organizations where method performance data are available. Currently, the Quantitative Method
584 is recommended by the EPA for use in supporting product claims designed to treat hard non-porous
585 surfaces contaminated with spores of *Clostridium difficile* (US EPA, 2018) and for cells of
586 *Candida auris* (US EPA, 2017), an emerging yeast pathogen. Additionally, the technical quality
587 and flexibility of ASTM E2197 for testing the effectiveness of antimicrobial substances against a
588 wide variety of microorganisms has been widely demonstrated in the published domain (Alhmid
589 et al., 2016; Cadnum et al., 2017; Cook et al., 2016; Kanamori et al., 2018; Majcher et al., 2008;

590 Sabbah et al., 2018; Sattar et al., 2003; Springthorpe et al., 2005, Springthorpe et al., 2007;
591 Uwamahoro et al., 2018).

592

593 Use of the Quantitative Method could potentially provide measurable benefits to regulators and
594 the stakeholder community due to its ease of use, clear interpretation of the quantitative results,
595 reduced laboratory biosafety hazards (e.g., reduced amount of inoculum required), likely reduction
596 in repeat testing, and the method's flexibility to accommodate multiple active ingredients and
597 microbes. The method also may be used to test spray product formulations (as liquids), thus
598 reducing the need for a separate spray test. The results presented here provide examples of how
599 the method may be successfully utilized for testing a variety of microbes. The current use of the
600 method by the EPA to support *C. difficile* and *C. auris* claims provide examples of its utility as a
601 regulatory procedure for testing high-consequence public health pathogens. The microorganisms
602 tested in our experiments are considered to be representatives of clinical pathogens; however,
603 individual regulatory authorities may require additional or alternative microorganisms to be tested
604 to support specific label claims. Furthermore, the LR data generated from this method may be used
605 to develop microbial kill curves for product research and development and may be useful in risk-
606 based analyses (Haas et al., 2014, US EPA 2012). In theory, for manufacturers seeking to market
607 products internationally, successful testing with an alternative harmonized method may allow for
608 product registration in other OECD member countries; thus minimizing pre-market costs and
609 providing regulators with simpler data sets to review and analyze. Harmonization of test
610 procedures could also benefit the end-users by the development of more consistent, streamlined
611 product use directions.

612

613 As demonstrated in this report, the availability of quantitative data allows for rigorous statistical
614 analyses to inform the end-user of the amount of potential variability associated with the untreated
615 control and treated populations of microbes on a hard, non-porous surface. Based on the
616 observations over the three multi-laboratory studies involving the measurement of LRs, it appears
617 that highly effective (e.g., $LR \geq 5.0$) antimicrobial treatments resulting in few to no surviving
618 microbes and antimicrobial treatments with limited effectiveness (e.g., $LR \leq 1.0$) exhibit greater
619 reproducibility. In contrast, antimicrobial treatments resulting in intermediate LR (e.g., 2.0 to 4.0)
620 show higher variability in the results, thus lower reproducibility. These general observations are
621 supported by a review conducted by Parker et al., 2018 which quantifies the relationship between
622 variability (i.e., S_R) and the associated mean LR for several antimicrobial test methods (including
623 ASTM E2197). A similar analysis of the trends in the current data set will be necessary to more
624 completely ascertain the relationship between the mean LR and the repeatability and
625 reproducibility of the Quantitative Method. Further, by understanding the level of variability
626 associated with the Quantitative Method, stakeholders and regulators may use the data to propose
627 appropriate LR-based product performance standards and testing criteria to ensure high confidence
628 in the outcome of the test. An example of this modeling exercise is provided in the reassessment
629 of the AOAC Use dilution Method's performance standards where a multi-laboratory collaborative
630 study was used to generate method performance data and variability values (Tomasino et al., 2014;
631 Parker et al., 2014). The statistical methodology utilizes error rates (i.e., Type I pass-error and
632 Type II fail-error) to formulate a set of testing criteria (e.g., number of independent tests and the
633 required LRs) necessary to achieve high confidence in the outcome of the tests. The approach can
634 accommodate criteria that require tests against different microbes, even potentially with different

635 levels of variability as we demonstrate here. The application of this statistical model on the current
636 data set will be covered under a separate report.

637

638 **References**

639 Abreu, A., Tavares, R., Borges, A., Mergulhao, F., Simoes, M. 2013. Current and
640 emergent strategies for disinfection of hospital environments. *Journal of Antimicrobial*
641 *Chemotherapy*. 68:2718-2732.

642 Agency for Healthcare Research and Quality (AHRQ), Technical Brief. 2015.
643 Environmental cleaning for the prevention of healthcare-associated infections. AHRQ
644 publication No. 15-EHC020-EF.

645 Alfa, M., Lo, E., Olson, N., MacRae, M., Buelow-Smith, L. 2015. Use of daily
646 disinfectants cleaner instead of a daily cleaner reduced hospital-acquired infection rates.
647 *American Journal of Infection Control*, 43: 141-146.

648 Alhmid, H., Koganti, S., Cadnum, J., Rai, H., Jencson, A., Donskey, C. 2016. Evaluation
649 of a Novel Alcohol-based Surface Disinfectant for Disinfection of hard and Soft Surfaces
650 in Healthcare Facilities. *Open Forum Infectious Diseases*. Brief Report. 1-3.

651

652

653 AOAC, *Guidelines for Collaborative Study Procedures to Validate Characteristics of a*
654 *Method of Analysis*, in *Official Methods of Analysis of AOAC International*. 2016.

655 AOAC Official Methods of Analysis. Testing disinfectants against *Staphylococcus*
656 *aureus*. Use-dilution method. 2012; 18th Ed., AOAC INTERNATIONAL, Gaithersburg,
657 MD, Method 955.15.

658 AOAC Official Methods of Analysis. Testing disinfectants against *Pseudomonas*
659 *aeruginosa*. Use-dilution method. 2012; 18th Ed., AOAC INTERNATIONAL,
660 Gaithersburg, MD, Method 964.02.

661 AOAC Official Methods of Analysis. Three Step Method. 18th Ed., AOAC
662 INTERNATIONAL, Gaithersburg, MD, Method 2008.05.

663 ASTM Standard E691, 2013. Standard Practice for Conducting an Interlaboratory Study
664 to Determine the Precision of a Test Method. ASTM International, West Conshohocken,
665 PA.

666 ASTM Standard E2197-17. 2017. Standard quantitative disk carrier test method for
667 determining the bactericidal, virucidal, fungicidal, mycobacterial, and sporicidal activities
668 of liquid chemical germicides.

669 ASTM Standard E2799-17. 2017. Standard Method for Testing Disinfectant Efficacy
670 against *Pseudomonas aeruginosa* Biofilm using the MBEC Assay. ASTM International,
671 West Conshohocken, PA.

672 Boyce, J., 2016. Modern technologies for improving cleaning and disinfection of
673 environmental surfaces in hospitals. Antimicrobial Resistance and Infection Control.
674 5:10.

675 Cadnum, J., Shaikh, A., Piedrahita, C., Sankar, T., Jencson, A., Larkin, E., Ghannoum,
676 M., Donskey, C. 2017. Effectiveness of Disinfectants against *Candida auris* and other

677 Candida Species. Infection Control and Hospital Epidemiology. Vol. 38, No. 10. 1240-
678 1243.

679 Cook, B., Cutts, T., Nikiforuk, A., Kobasa, D., Theriault, S. 2016. The Disinfection
680 Characteristics of Ebola Virus Outbreak Variants. Scientific Reports. 6:38293

681 Dancer, S., 2014. Controlling hospital-acquired infection: focus on the role of the
682 environment and new technologies for decontamination. 27 (4) 665-690.

683 Donskey, C., 2013. Does improving surface cleaning and disinfection reduce health care-
684 associated infections? American Journal of Infection Control. 41: s12-s19.

685 Haas, Rose, Gerba. QMRA. John Wiley, 2014

686 Hamilton, M., Hamilton, G., Goeres, D., Parker, A., 2013. Guidelines for the statistical
687 analysis of a collaborative study of a laboratory method for testing disinfectant product
688 performance. J. AOAC Int. Vol. 96 (5), 1138-1151. [https://doi.org/10.5740/jaoacint.12-](https://doi.org/10.5740/jaoacint.12-217)
689 217

690 Hamilton, M. 2011. Montana State University Center for Biofilm Engineering.
691 Knowledge Sharing Articles. KSA-SM-011: How to decide whether reproducibility
692 standard deviation is small enough.

693 Hamilton MA, Parker AE “KSA-SM-06—Enumerating viable cells by pooling counts for
694 several dilutions,” Knowledge Sharing Articles, Center for Biofilm Engineering at
695 Montana State University, Bozeman, MT. September 22, 2010

696 Hota, B., 2004. Contamination, disinfection, and cross-colonization: are hospital surfaces
697 reservoirs for nosocomial infection? Clinical Infectious Diseases. 39: 1189-1189.

698 Kanamori, H., Rutala, W., Gergen, M., Sickbert-Bennett, E., Weber, D. 2018. Germicidal
699 Activity against Carbapenem/Colistin-Resistant *Enterobacteriaceae* Using a Quantitative
700 Carrier Test Method. *Antimicrobial Agents and Chemotherapy*. 62:7.

701 Majcher, M., Bernard, K., Sattar, S. 2008. Identification by quantitative carrier test of
702 surrogate spore-forming bacteria to assess sporicidal chemicals for use against *Bacillus*
703 *anthracis*. *Applied and Environmental Microbiology*. 74: 676-681.

704 Organisation for Economic Co-operation and Development (OECD). 2009. Guidance
705 Document for the Development of OECD Guidelines for the Testing of Chemicals.
706 OECD Environmental Health and Safety Publications. Series on Testing and Assessment.
707 Number 1.

708 Organisation for Economic Co-operation and Development (OECD). 2011. Series on
709 Testing and Assessment: Other (e.g., Pesticide residue chemistry, biocides efficacy,
710 miscellaneous). No. 154. Validation report: validation of efficacy methods for
711 antimicrobials used on hard surfaces, Part 1 and Part 2.

712 Organisation for Economic Co-operation and Development. 2018. About the OECD.
713 <http://www.oecd.org/about/whodoeswhat/>.

714 Parker, A., Hamilton, M., 2011. Assessing resemblance, repeatability and reproducibility
715 for quantitative methods. Center for Biofilm, Engineering, KSA-SM-10
716 (<http://www.biofilm.montana.edu/content/ksa-sm-10>).

717 Parker, A., Hamilton, M., 2013. Using R to assess resemblance, repeatability, and
718 reproducibility for quantitative and semi-quantitative disinfectant methods. Center for

719 Biofilm, Engineering, KSA-SM-13 (<http://www.biofilm.montana.edu/content/ksa-sm->
720 13).

721 Parker, A., Tomasino, S., Hamilton, M.A., 2014. Statistical model for assessing
722 performance standards for quantitative and semi-quantitative disinfectant test methods. J
723 AOAC Int. Vol. 97 (1), 58–67. <https://doi.org/10.5740/jaoacint.13-105>

724 Parker, A., Walker, D., Goeres, D., Olson, M., Omar, A. 2014. Ruggedness and
725 reproducibility of the MBEC biofilm disinfectant efficacy test. Journal of
726 Microbiological Methods. 102 55-64.

727 Parker, A., Hamilton, M., Goeres, D. 2018. Reproducibility of antimicrobial test
728 methods. Scientific Reports. 8:12531.

729 Pinheiro, J.C. and D.M. Bates, *Mixed-Effects Models in S and S-PLUS*. 1st ed. 2000.
730 Corr. 3rd printing 2002 edition ed. 2002, New York: Springer. 528.

731 Pinheiro, J.C., et al., *nlme: Linear and Nonlinear Mixed Effects Models*. 2017.

732 Quinn, M., Henneberger, P., Braun, B., Delclos, G., Fagan, K., Huang, V., Knaack, J.,
733 Kusek, L., Lee, S., Le Moual, N., Maher, K., McCrone, S., Mitchell, A., Pechter, E.,
734 Rosenman, K., Schulster, L., Stephens, A., Wilburn, S., Zock, J. 2015. Cleaning and
735 disinfecting environmental surfaces in health care: toward an integrated framework for
736 infection and occupational illness prevention. 43: 424-434.

737 R Core Team, *R: A language and environment for statistical computing*. 2017, R
738 Foundation for Statistical Computing: Vienna, Austria.

739 Rutala, W., Weber, D., Disinfectants used for environmental disinfection and new room
740 technology. 2013. American Journal of Infection Control. 41: S36-S41.

741 Sabbah, S., Springthorpe, S., Sattar, S. 2010. Use of a Mixture of Surrogates for
742 Infectious Bioagents in a Standard Approach to Assessing Disinfection of Environmental
743 Surfaces. 2010. Applied and Environmental Microbiology. Vol. 76. No. 17. Pp. 6020-
744 6022.

745 Sattar, S., Springthorpe, S., Abegbunrin, A., Zafer, A., Busa, M. 2003. A disc-based
746 quantitative carrier test method to assess the virucidal activity of chemical germicides.
747 Journal of Virological Methods. 112: 3-12.

748 Springthorpe, S., Sattar, S., 2005. Carrier tests to assess microbicidal activities of
749 chemical disinfectants for use on medical devices and environmental surfaces. J AOAC
750 Int. Vol. 88 (1), 182-201.

751 Springthorpe, S., Sattar, S., 2007. Application of a quantitative carrier test to evaluate
752 microbicides against mycobacteria. J. AOAC Int. Vol. 9 (3), 817-824.

753

754 Tilt, N., Hamilton, M. 1999. Repeatability and reproducibility of germicide tests: a
755 literature review. J AOAC Int. 82 (2), 384-389.

756 Tomasino, S., Blackburn, T., Hardy, J., 2021. Regulation of Antimicrobial Pesticides by
757 the US Environmental Protection Agency. Chapter 72. Block's Disinfection, Sterilization
758 and Preservation. Sixth edition.

759 Tomasino, S., Hamilton, M., 2006. Modification to the AOAC sporicidal activity of
760 disinfectants test (method 966.04): collaborative study. J. AOAC Int. Vol. 89, (5). 1373-
761 1397.

762 Tomasino, S., Parker, A., Hamilton, M., Hamilton, G., 2012. Performance of the AOAC
763 use-dilution method with targeted modifications: collaborative study. J. AOAC Int. 95
764 (6), 1618-1628. <https://doi.org/10.5740/jaoacint.12-170>

765
766 Tomasino, S., Parker, A., Hamilton, M., 2014. Use of statistical modeling to reassess the
767 performance standard for the AOAC use-dilution methods (955.15 and 964.02). J. AOAC
768 Int. Vol. 97 (1), 68-77. <https://doi.org/10.5740/jaoacint.13-216>

769 Tomasino S., Pines, R., Cottrill, M. 2008. Determining the efficacy of liquid sporicides
770 against spores of *Bacillus subtilis* on a hard nonporous surface using the quantitative
771 three step method: collaborative study. J. AOAC Int. Vol. 91 (4), 833-852.

772

773

774 Tomasino SF, Pines RM, Hamilton MA, 2009. Improving the AOAC use-dilution
775 method by establishing a minimum log density value for test microbes on inoculated
776 carriers. J. AOAC Int., 92 (5), 1531-1540.

777 Tomasino SF, Pines RM, Hamilton GC, 2012. Procedural revision to the use-dilution
778 method: establishment of maximum log density value for test microbes on inoculated
779 carriers. J. AOAC Int. Vol. 95 (4), 1059-1063. <https://doi.org/10.5740/jaoacint.12-171>

780 United States Environmental Protection Agency. CFR, Title 40—Protection of
781 Environment chapter 1-Part 160—Good Laboratory Practice Standards).

782 United States Environmental Protection Agency, 1997. EPA Good Laboratory Practice
783 Standards (Code of Federal Regulations, Title 40, Volume 14, Parts 150 to 189)

784 United States Environmental Protection Agency, 2012. Microbial Risk Assessment
785 Guideline: Pathogenic Microorganisms with Focus on Food and
786 Water. [https://www.epa.gov/risk/microbial-risk-assessment-guideline-pathogenic-](https://www.epa.gov/risk/microbial-risk-assessment-guideline-pathogenic-microorganisms-focus-food-and-water)
787 [microorganisms-focus-food-and-water](https://www.epa.gov/risk/microbial-risk-assessment-guideline-pathogenic-microorganisms-focus-food-and-water)

788
789 United States Environmental Protection Agency, 2012. Office of Chemical Safety and
790 Pollution Prevention Harmonized Test Guidelines. Antimicrobial Test Guidelines. Series
791 810.2000–Product Performance Test Guidelines for Public Health Uses of Antimicrobial
792 Agents. http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series810.htm

793 United States Environmental Protection Agency, 2016. Method Validation of U.S.
794 Environmental Protection Agency Microbiological Methods of Analysis Prepared for:
795 The EPA Forum on Environmental Measurements (FEM) Prepared by: The FEM
796 Microbiology Action Team FEM Document Number 2009-01.

797
798 United States Environmental Protection Agency, 2017. Methods and Guidance for
799 Testing the Efficacy of Antimicrobial Products Against Biofilms on Hard, Non-Porous
800 Surfaces. [https://www.epa.gov/pesticide-analytical-methods/methods-and-guidance-](https://www.epa.gov/pesticide-analytical-methods/methods-and-guidance-testing-efficacy-antimicrobial-products-against)
801 [testing-efficacy-antimicrobial-products-against](https://www.epa.gov/pesticide-analytical-methods/methods-and-guidance-testing-efficacy-antimicrobial-products-against)

802 United States Environmental Protection Agency, 2018. Methods and Guidance for
803 Testing the Efficacy of Antimicrobial Products Against Spores of *Clostridium difficile* on
804 Hard Non-Porous Surfaces. [https://www.epa.gov/pesticide-registration/methods-and-](https://www.epa.gov/pesticide-registration/methods-and-guidance-testing-efficacy-antimicrobial-products-against-spores)
805 [guidance-testing-efficacy-antimicrobial-products-against-spores.](https://www.epa.gov/pesticide-registration/methods-and-guidance-testing-efficacy-antimicrobial-products-against-spores)

806


807 Uwamahoro, M., Massicotte, R., Hurtubise, Y., Gagne-Bourque, F., Mafu, A., Yahia, L.,

808 Evaluating the Sporicidal Activity of Disinfectants against *Clostridium difficile* and

809 *Bacillus amyloliquefaciens* Spores by Using the Improved Methods Based on ASTM

810 E2197-11. 2018. *Frontiers in Public Health*. Vol. 6. Article 18:1-6.

811



812

813 **Figure 1.** The LRs for *P. aeruginosa* and *S. aureus* for the NaOCl treatments in Study one (2012).


814 Each point is a LR for a single test. Horizontal black lines indicate the mean LR for each

815 treatment. Different colors and symbols are used to differentiate the treatments. Some horizontal

816 jitter has been added to the data to help with visualization.

817


818



819

820 **Figure 2.** The LR_s for *P. aeruginosa* and *S. aureus* for the phenolic, hydrogen peroxide, citric
 821 acid, and quaternary ammonium treatments in Study one (2012). Each point is a LR for a single
 822 test. Horizontal black lines indicate the mean LR for each treatment. Different colors and
 823 symbols are used to differentiate the treatments. Some horizontal jitter has been added to the
 824 data to help with visualization.

825




826

827 **Figure 3.** LRs for *P. aeruginosa* and *S. aureus* from Study two (2014). Each point is a log
 828 reduction for a single test. Different colors and symbols are used to differentiate the treatments.
 829 Horizontal black lines indicate the mean LR for each treatment. Some horizontal jitter has been
 830 added to the data to help with visualization.

831

832

833



834

835 **Figure 4.** LRs for *M. terrae* for the NaOCl, phenolic, hydrogen peroxide, citric acid and
 836 quaternary ammonium treatments in Study three (2013). Each point is a log reduction for a
 837 single test. Different colors and symbols are used to differentiate the treatments. Horizontal
 838 black lines indicate the mean LR for each treatment. Some horizontal jitter has been added to
 839 the data to help with visualization.

840

841

842

843

844

845

846

847

848


849

850 **Supplementary Material**

851 Plots of the control count data are provided for each of the 4 studies in the following 4 sections.

852 **S.1 Study one**

853



854


855 **Figure S1.** The untreated controls for *P. aeruginosa* and *S. aureus* for the NaOCl treatments in
856 Study one (2012). Each point is the log (CFU/carrier) for a single carrier. Some horizontal jitter
857 has been added to the data to help with visualization.

858

859

860

861



862

863 **Figure S2.** The untreated controls for *P. aeruginosa* and *S. aureus* for the phenolic, hydrogen
864 peroxide, citric acid, and quaternary ammonium treatments in Study one (2012). Each point is
865 the log (CFU/carrier) for a single carrier. Some horizontal jitter has been added to the data to
866 help with visualization.

867

868

869

870

871

872

873


874

875

876

877

878 **S.2 Study two**



879

880 **Figure S3.** Untreated controls for *P. aeruginosa* and *S. aureus* from Study 2 (2014). Each point

881 is the \log_{10} (CFU/carrier) for a single control carrier in a test. Some horizontal jitter has been

882 added to the data to help with visualization.

883

884

885

886

887

888

889


890

891

892

893

894 **S.3 Study three**



895

896 **Figure S4.** Untreated controls for *M. terrae* from Study three (2013). Each point is the log₁₀
897 (CFU/carrier) for a single control carrier in a test. Some horizontal jitter has been added to the
898 data to help with visualization.

899

900

901

902

903

904

905


906

907

908

909

910 **S.4 Study four**



911

912 **Figure S5.** Untreated controls for *M. terrae* from Study four (2014). Each point is the log₁₀
 913 (CFU/carrier) for a single control carrier in a test. Some horizontal jitter has been added to the
 914 data to help with visualization.

915